Bone Biologics Corporation (BBLG)
Total Valuation
Bone Biologics has a market cap or net worth of $2.43 million. The enterprise value is -$2.02 million.
| Market Cap | 2.43M |
| Enterprise Value | -2.02M |
Important Dates
The last earnings date was Tuesday, November 14, 2023, after market close.
| Earnings Date | Nov 14, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 538,438 shares outstanding. The number of shares has increased by 808.48% in one year.
| Shares Outstanding | 538,438 |
| Shares Change (YoY) | +808.48% |
| Shares Change (QoQ) | +199.36% |
| Owned by Insiders (%) | 5.98% |
| Owned by Institutions (%) | 22.82% |
| Float | 345,226 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.64 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.21, with zero debt.
| Current Ratio | 4.21 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -142.90% and return on invested capital (ROIC) is -251.96%.
| Return on Equity (ROE) | -142.90% |
| Return on Assets (ROA) | -93.30% |
| Return on Capital (ROIC) | -251.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.25M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1,600 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.54% in the last 52 weeks. The beta is 0.51, so Bone Biologics's price volatility has been lower than the market average.
| Beta (1Y) | 0.51 |
| 52-Week Price Change | -90.54% |
| 50-Day Moving Average | 4.00 |
| 200-Day Moving Average | 20.90 |
| Relative Strength Index (RSI) | 56.21 |
| Average Volume (30 Days) | 272,781 |
Short Selling Information
The latest short interest is 30,016, so 5.57% of the outstanding shares have been sold short.
| Short Interest | 30,016 |
| Short Previous Month | 51,561 |
| Short % of Shares Out | 5.57% |
| Short % of Float | 8.69% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.56M |
| Pretax Income | -6.51M |
| Net Income | -6.51M |
| EBITDA | -6.51M |
| EBIT | -6.51M |
| Earnings Per Share (EPS) | -$49.60 |
Balance Sheet
The company has $4.45 million in cash and no debt, giving a net cash position of $4.45 million or $8.27 per share.
| Cash & Cash Equivalents | 4.45M |
| Total Debt | n/a |
| Net Cash | 4.45M |
| Net Cash Per Share | $8.27 |
| Equity / Book Value | 3.79M |
| Book Value Per Share | 7.04 |
| Working Capital | 3.79M |
Cash Flow
| Operating Cash Flow | -9.49M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.49M |
| FCF Per Share | -$24.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bone Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -267.30% |
| FCF Yield | -389.88% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -808.48% |
| Shareholder Yield | -808.48% |
Analyst Forecast
The average price target for Bone Biologics is $67.50, which is 1,393.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $67.50 |
| Price Target Difference | 1,393.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 20, 2023. It was a reverse split with a ratio of 1:8.
| Last Split Date | Dec 20, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |